Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million ...
Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...
As the March 31, 2026, capitalization deadline draws near, the Nigerian banking sector is witnessing a seismic shift, not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback